Latest News: Proscia Receives FDA 510(k) Clearance For Concentriq AP-DxREAD THE PRESS RELEASE

Proscia’s AI Technology Accurately Identifies Melanomas in Prospective Study

Proscia
By Author Proscia | October 5, 2021

Results of a prospective study just released demonstrate that an artificial intelligence (AI) technology solution from Proscia can automatically detect melanoma with a high degree of accuracy.

Conducted at Thomas Jefferson University in Philadelphia and the University of Florida, the study assessed the the real-world performance of Proscia’s technology on an uncurated set of 1,422 sequential skin biopsies. The technology correctly identified invasive melanoma and melanoma in situ with a sensitivity of 93% and a specificity of 91%. It also classified basal cell carcinoma and squamous cell carcinoma with an AUC of .97 and .95, respectively, accounting for a combined 97% of all skin cancers. This study validated the results of a multi-site retrospective study of 12,784 images, which will be presented during the Computational Challenges in Digital Pathology Workshop at the 2021 International Conference on Computer Vision.

Our website uses cookies. By using this site, you agree to its use of cookies.